Thank you, Mr. Chairman, ladies and gentlemen. Thank you very much for inviting Genome Canada to come here in front of this committee on Bill C-2.
First, you will find that we have provided you with a package of all of our information, and we have provided you with one table. To make your life simple since your time is very important, we would like to attract your attention to a very simple table.
First, I have to make a statement that Genome Canada is a private, not-for-profit corporation, incorporated in February 2000 under the Canada Corporations Act, part II. For any attorneys in the room, you will understand what this means: it is not a federal agency and it is not based on an act of the Parliament. Genome Canada was created by the private sector, and pretty much like Mrs. Sharpe just mentioned, it's managed like a venture capital company and was created by entrepreneurs and scientists. Genome Canada operates at arm's length from government. It is not a department, an agency, or a crown corporation. It is not subject to the Financial Administration Act. Industry Canada's relationship with Genome Canada is governed by a funding agreement.
You will find in the package the following three documents. First, there are the bylaws of Genome Canada. We will not provide you with the corporate governance manual, because of its thickness, but if you need any information in your deliberations, we encourage you to look in the table at the column “Corporate Governance Manual” and you will find all of the items there, and we'd be delighted to provide you with that information.
In the package we have also provided you with the latest funding agreement with Industry Canada, and finally, you will find the corporate plan that was submitted to Industry Canada in February 2006, the latest version that we have. And for transparency, we have also provided you with the high-level cashflow of all the revenues and investments—actual, present and future—of Genome Canada.
Like any private corporation, Genome Canada is governed by a board of directors, elected from among the directors. So it's like a corporation; we select who should be on the board, and we consult the minister for advice, but the directors are not nominated by the Government of Canada. We want to ensure that we cover all the regions of Canada, the genders, and the attributes of our board members. We have a board of sixteen people, five of whom are ex officio, including the president of the Canadian Institutes of Health Research; the president of NSERC, the Natural Sciences and Engineering Research Council of Canada; the president of the Social Sciences and Humanities Research Council of Canada, the third granting council; and finally, the president of the National Research Council.
The reason that the presidents of all of these research council agencies are ex officio members of the board of Genome Canada is to ensure that we are not duplicating what these agencies are doing so well.
We have all of the committees that a typical—even publicly traded—company has, from an executive committee to compensation, audit, investment, election, and corporate governance committees. So that takes care of governance.
We have internal policies, but most of the policies are directed by the agreement that we signed with Industry Canada, from whistle-blowing to reporting, to membership and investment policy—because we manage a substantial amount of funds—emerging policies, a data release policy, confidentiality, and conflict of interest. You have the whole list there in front of you.
On the accountability side, I would again attract your attention to the funding agreement with Industry Canada. We have to produce annually a corporate plan, which we hope Industry Canada can table before Parliament. This corporate plan includes the planned expenditures, the objectives of Genome Canada for the next years, and performance expectations. We just went through a compliance audit, mandated by Industry Canada, to make sure that Genome Canada is in compliance with the funding agreement. And those are all the accountability issues.
We're here to answer your questions. We feel that Bill C-2 as it is right now has no impact on Genome Canada.